Loading interface...

Glyxambi 25 mg/5 mg Tablets

Manufactured byBOEHRINGER INGELHEIM INDIA PVT LTD
ContainsEmpagliflozin (25 mg) + Linagliptin (5 mg)
Description

Glyxambi 25 mg/5 mg Tablets is a combination medicine used for the treatment of type 2 diabetes mellitus. It is also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and heart diseases. Patients are advised to follow a strict diet and exercise regimen along with this medicine for the best possible effect. This medicine is not recommended for use in patients below 18 years of age.

Side effects

Major & minor side effects for Glyxambi 25 mg/5 mg Tablets

  • Bladder pain
  • Bloody or cloudy urine
  • Difficult or painful urination
  • Lower back pain
  • Fast heartbeat
  • Headache
  • Unusual tiredness or weakness
  • Nausea and vomiting
  • Inflammation of pancreas
  • Blurred vision
  • Sore throat
  • Cough
  • Itching and skin rash

Uses of Glyxambi 25 mg/5 mg Tablets

What is it prescribed for?

  • Type II Diabetes Mellitus
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to show its action is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of severe adverse effects. Avoid performing activities that need high mental alertness like driving a vehicle or operating heavy machinery if alcohol and this medicine are used together.
  • Is this a habit forming medicine?
    No habit-forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to empagliflozin, linagliptin, or any other inactive ingredients present in the formulation.

Moderate to Severe Renal impairment

This medicine is not recommended for use in patients with moderate to severe renal function impairment due to the increased risk of worsening of the patient's condition.

Type 1 Diabetes mellitus

This medicine is not recommended for use in patients with type 1 diabetes mellitus since it is not effective in treating this condition.

Diabetic ketoacidosis (Increased ketone bodies in blood)

This medicine is not recommended for use in patients with diabetic ketoacidosis due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition.
General warnings

Hypotension

This medicine should be used with caution in patients with hypotension due to the increased risk of adverse effects. Correct the volume status before initiating treatment with this medicine. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. Replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Kidney diseases

This medicine should be used with caution in patients with kidney disease due to the increased risk of worsening of the patient's condition. Close monitoring of kidney function tests, appropriate dose adjustments, or replacement with a suitable alternative may be required based on the clinical condition.

Genital mycotic infections

This medicine should be used with caution in patients with genital mycotic infections due to the risk of worsening of the condition. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Increased low-density lipoprotein cholesterol

This medicine should be used with caution in patients with hyperlipidemia since it may increase the blood levels of LDL cholesterol. Regular monitoring of the lipid levels is required while using this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Urosepsis

This medicine should be used with caution in patients with urinary tract infections due to the risk of worsening of the condition. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Hypoglycemia

Use of this medicine may cause hypoglycemia when used along with insulin and insulin secretagogues in some patients. This risk is especially higher in patients suffering from kidney diseases, malnourishment, pituitary gland diseases, etc. Close monitoring of blood glucose levels is recommended for such patients. Appropriate dose adjustments may be required based on the clinical condition. Your doctor may advise you to carry sugar candy to counteract the effects of low blood sugar levels (hypoglycemia).

Bullous pemphigoid

This medicine should be used with caution due to the increased risk of bullous pemphigoid, a hypersensitivity reaction of the skin. Any unusual symptoms such as skin blisters or skin rashes should be reported to the doctor on priority. Therapy with this medicine may be discontinued and an alternative treatment option should be considered in such cases based on the clinical condition.

Arthralgia

This medicine should be used with caution in patients with a known history of severe arthralgia due to the increased risk of worsening of the patient's condition. Close monitoring of patient's condition, appropriate dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Use in pediatrics

This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Driving or Operating machinery

Use of this medicine may cause blurred vision or dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Missed Dose

Take the missed dose as soon as you remember it. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

N/A

Instructions

Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of severe adverse effects. Avoid performing activities that need high mental alertness like driving a vehicle or operating heavy machinery if alcohol and this medicine are used together.
Interaction with Medicine

Aripiprazole

Clozapine

Dexamethasone

Dopamine

Acetazolamide

Gatifloxacin

Bexarotene

Amlodipine

Chlorthalidone

Carvedilol

Disease interactions

Hyperlipidemia

This medicine should be used with caution in patients with hyperlipidemia since it may increase the blood levels of LDL cholesterol. Regular monitoring of the lipid levels is required while using this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Hypotension

This medicine should be used with caution in patients with hypotension due to the increased risk of adverse effects. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. Replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Pancreatitis

This medicine should be used with extreme caution in patients with a known history of pancreatitis due to the increased risk of recurrent pancreatitis. Report any symptoms such as abdominal pain, nausea, vomiting, etc. to the doctor immediately. Your doctor may advise you to discontinue this medicine in such cases. An alternative treatment option should be considered based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
Take this medicine exactly as instructed by the doctor. It can be taken with or without food. Do not take in larger or smaller amounts than advised/prescribed. Regular monitoring of blood sugar levels is recommended during treatment with this medicine. Consult the doctor if you experience any undesirable side effects. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
Empagliflozin reduces glucose reabsorption from the kidneys and lowers the blood glucose levels. Linagliptin increases insulin and lowers glucagon production. This results in a reduction of blood glucose levels.
Legal Status

Unknown

Approved

Approved

Approved

Classification

Category

Antidiabetic combinations, SGLT-2 inhibitors, Dipeptidyl peptidase 4 inhibitors

Schedule

Schedule H

[Internet]. Ema.europa.eu. 2019 [cited 13 May 2019]. Available from:

https://www.ema.europa.eu/en/documents/product-information/glyxambi-epar-product-information_en.pdf

DailyMed - GLYXAMBI- empagliflozin and linagliptin tablet, film coated [Internet]. Dailymed.nlm.nih.gov. 2019 [cited 13 May 2019]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ddbab689-f76c-488c-9613-4168d41dd730

TGA eBS - Product and Consumer Medicine Information Licence [Internet]. Ebs.tga.gov.au. 2019 [cited 13 May 2019]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-01012-1&d=201905131016933

Type 2 Diabetes Medication | GLYXAMBI® (empagliflozin/linagliptin) tablets [Internet]. Glyxambi.com. 2019 [cited 13 May 2019]. Available from:

https://www.glyxambi.com/
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 15 May 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.